Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis
In short
Sustained clinical adoption has strengthened performance expectations for the pharmaceutical manufacturer through the middle of the decade. Market demand for the blood thinner medication Eliquis continues to outperform baseline projections. Consequently, Pfizer has officially elevated its overall financial forecast for the 2026 fiscal year.
Key points
- Strong ongoing sales of the blood thinner Eliquis are boosting the drugmaker's multi-year…: Strong ongoing sales of the blood thinner Eliquis are boosting the drugmaker's multi-year outlook.
- Management updated its 2026 financial guidance in response to sustained commercial produc…: Management updated its 2026 financial guidance in response to sustained commercial product demand.
- Eliquis continues to act as a significant growth catalyst for the company's financial fut…: Eliquis continues to act as a significant growth catalyst for the company's financial future.